Loss of SETD2 Induces a Metabolic Switch in Renal Cell Carcinoma Cell Lines toward Enhanced Oxidative Phosphorylation

Jingping Liu, Paul D. Hanavan, Katon Kras, Yvette W. Ruiz, Erik P. Castle, Douglas Lake, Xianfeng Chen, Daniel O'Brien, Huijun Luo, Keith D. Robertson, Haiwei Gu, Thai H. Ho

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

SETD2, a histone H3 lysine trimethyltransferase, is frequently inactivated and associated with recurrence of clear cell renal cell carcinoma (ccRCC). However, the impact of SETD2 loss on metabolic alterations in ccRCC is still unclear. In this study, SETD2 null isogenic 38E/38F clones derived from 786-O cells were generated by zinc finger nucleases, and subsequent metabolic, genomic, and cellular phenotypic changes were analyzed by targeted metabolomics, RNA sequencing, and biological methods, respectively. Our results showed that compared with parental 786-O cells, 38E/38F cells had elevated levels of MTT/Alamar blue levels, ATP, glycolytic/mitochondrial respiratory capacity, citrate synthase (CS) activity, and TCA metabolites such as aspartate, malate, succinate, fumarate, and α-ketoglutarate. The 38E/38F cells also utilized alternative sources beyond pyruvate to generate acetyl-CoA for the TCA cycle. Moreover, 38E/38F cells showed disturbed gene networks mainly related to mitochondrial metabolism and the oxidation of fatty acids and glucose, which was associated with increased PGC1α, mitochondrial mass, and cellular size/complexity. Our results indicate that SETD2 deficiency induces a metabolic switch toward enhanced oxidative phosphorylation in ccRCC, which can be related to PGC1α-mediated metabolic networks. Therefore, this current study lays the foundation for the further development of a global metabolic analysis of cancer cells in individual patients, which ultimately will have significant potential for the discovery of novel therapeutics and precision medicine in SETD2-inactivated ccRCC.

Original languageEnglish (US)
Pages (from-to)331-340
Number of pages10
JournalJournal of Proteome Research
Volume18
Issue number1
DOIs
StatePublished - Jan 4 2019

Fingerprint

Oxidative Phosphorylation
Renal Cell Carcinoma
Cells
Switches
Cell Line
Citrate (si)-Synthase
Fumarates
Acetyl Coenzyme A
Succinic Acid
Metabolites
Pyruvic Acid
Metabolism
Aspartic Acid
Histones
Lysine
Medicine
Zinc
Fatty Acids
Genes
Adenosine Triphosphate

Keywords

  • clear cell renal cell carcinoma (ccRCC)
  • mitochondria
  • oxidative phosphorylation
  • PGC1α
  • SETD2

ASJC Scopus subject areas

  • Biochemistry
  • Chemistry(all)

Cite this

Loss of SETD2 Induces a Metabolic Switch in Renal Cell Carcinoma Cell Lines toward Enhanced Oxidative Phosphorylation. / Liu, Jingping; Hanavan, Paul D.; Kras, Katon; Ruiz, Yvette W.; Castle, Erik P.; Lake, Douglas; Chen, Xianfeng; O'Brien, Daniel; Luo, Huijun; Robertson, Keith D.; Gu, Haiwei; Ho, Thai H.

In: Journal of Proteome Research, Vol. 18, No. 1, 04.01.2019, p. 331-340.

Research output: Contribution to journalArticle

Liu, J, Hanavan, PD, Kras, K, Ruiz, YW, Castle, EP, Lake, D, Chen, X, O'Brien, D, Luo, H, Robertson, KD, Gu, H & Ho, TH 2019, 'Loss of SETD2 Induces a Metabolic Switch in Renal Cell Carcinoma Cell Lines toward Enhanced Oxidative Phosphorylation', Journal of Proteome Research, vol. 18, no. 1, pp. 331-340. https://doi.org/10.1021/acs.jproteome.8b00628
Liu, Jingping ; Hanavan, Paul D. ; Kras, Katon ; Ruiz, Yvette W. ; Castle, Erik P. ; Lake, Douglas ; Chen, Xianfeng ; O'Brien, Daniel ; Luo, Huijun ; Robertson, Keith D. ; Gu, Haiwei ; Ho, Thai H. / Loss of SETD2 Induces a Metabolic Switch in Renal Cell Carcinoma Cell Lines toward Enhanced Oxidative Phosphorylation. In: Journal of Proteome Research. 2019 ; Vol. 18, No. 1. pp. 331-340.
@article{5886d5cf3c0d43cf8af24cdc93d7fcf3,
title = "Loss of SETD2 Induces a Metabolic Switch in Renal Cell Carcinoma Cell Lines toward Enhanced Oxidative Phosphorylation",
abstract = "SETD2, a histone H3 lysine trimethyltransferase, is frequently inactivated and associated with recurrence of clear cell renal cell carcinoma (ccRCC). However, the impact of SETD2 loss on metabolic alterations in ccRCC is still unclear. In this study, SETD2 null isogenic 38E/38F clones derived from 786-O cells were generated by zinc finger nucleases, and subsequent metabolic, genomic, and cellular phenotypic changes were analyzed by targeted metabolomics, RNA sequencing, and biological methods, respectively. Our results showed that compared with parental 786-O cells, 38E/38F cells had elevated levels of MTT/Alamar blue levels, ATP, glycolytic/mitochondrial respiratory capacity, citrate synthase (CS) activity, and TCA metabolites such as aspartate, malate, succinate, fumarate, and α-ketoglutarate. The 38E/38F cells also utilized alternative sources beyond pyruvate to generate acetyl-CoA for the TCA cycle. Moreover, 38E/38F cells showed disturbed gene networks mainly related to mitochondrial metabolism and the oxidation of fatty acids and glucose, which was associated with increased PGC1α, mitochondrial mass, and cellular size/complexity. Our results indicate that SETD2 deficiency induces a metabolic switch toward enhanced oxidative phosphorylation in ccRCC, which can be related to PGC1α-mediated metabolic networks. Therefore, this current study lays the foundation for the further development of a global metabolic analysis of cancer cells in individual patients, which ultimately will have significant potential for the discovery of novel therapeutics and precision medicine in SETD2-inactivated ccRCC.",
keywords = "clear cell renal cell carcinoma (ccRCC), mitochondria, oxidative phosphorylation, PGC1α, SETD2",
author = "Jingping Liu and Hanavan, {Paul D.} and Katon Kras and Ruiz, {Yvette W.} and Castle, {Erik P.} and Douglas Lake and Xianfeng Chen and Daniel O'Brien and Huijun Luo and Robertson, {Keith D.} and Haiwei Gu and Ho, {Thai H.}",
year = "2019",
month = "1",
day = "4",
doi = "10.1021/acs.jproteome.8b00628",
language = "English (US)",
volume = "18",
pages = "331--340",
journal = "Journal of Proteome Research",
issn = "1535-3893",
publisher = "American Chemical Society",
number = "1",

}

TY - JOUR

T1 - Loss of SETD2 Induces a Metabolic Switch in Renal Cell Carcinoma Cell Lines toward Enhanced Oxidative Phosphorylation

AU - Liu, Jingping

AU - Hanavan, Paul D.

AU - Kras, Katon

AU - Ruiz, Yvette W.

AU - Castle, Erik P.

AU - Lake, Douglas

AU - Chen, Xianfeng

AU - O'Brien, Daniel

AU - Luo, Huijun

AU - Robertson, Keith D.

AU - Gu, Haiwei

AU - Ho, Thai H.

PY - 2019/1/4

Y1 - 2019/1/4

N2 - SETD2, a histone H3 lysine trimethyltransferase, is frequently inactivated and associated with recurrence of clear cell renal cell carcinoma (ccRCC). However, the impact of SETD2 loss on metabolic alterations in ccRCC is still unclear. In this study, SETD2 null isogenic 38E/38F clones derived from 786-O cells were generated by zinc finger nucleases, and subsequent metabolic, genomic, and cellular phenotypic changes were analyzed by targeted metabolomics, RNA sequencing, and biological methods, respectively. Our results showed that compared with parental 786-O cells, 38E/38F cells had elevated levels of MTT/Alamar blue levels, ATP, glycolytic/mitochondrial respiratory capacity, citrate synthase (CS) activity, and TCA metabolites such as aspartate, malate, succinate, fumarate, and α-ketoglutarate. The 38E/38F cells also utilized alternative sources beyond pyruvate to generate acetyl-CoA for the TCA cycle. Moreover, 38E/38F cells showed disturbed gene networks mainly related to mitochondrial metabolism and the oxidation of fatty acids and glucose, which was associated with increased PGC1α, mitochondrial mass, and cellular size/complexity. Our results indicate that SETD2 deficiency induces a metabolic switch toward enhanced oxidative phosphorylation in ccRCC, which can be related to PGC1α-mediated metabolic networks. Therefore, this current study lays the foundation for the further development of a global metabolic analysis of cancer cells in individual patients, which ultimately will have significant potential for the discovery of novel therapeutics and precision medicine in SETD2-inactivated ccRCC.

AB - SETD2, a histone H3 lysine trimethyltransferase, is frequently inactivated and associated with recurrence of clear cell renal cell carcinoma (ccRCC). However, the impact of SETD2 loss on metabolic alterations in ccRCC is still unclear. In this study, SETD2 null isogenic 38E/38F clones derived from 786-O cells were generated by zinc finger nucleases, and subsequent metabolic, genomic, and cellular phenotypic changes were analyzed by targeted metabolomics, RNA sequencing, and biological methods, respectively. Our results showed that compared with parental 786-O cells, 38E/38F cells had elevated levels of MTT/Alamar blue levels, ATP, glycolytic/mitochondrial respiratory capacity, citrate synthase (CS) activity, and TCA metabolites such as aspartate, malate, succinate, fumarate, and α-ketoglutarate. The 38E/38F cells also utilized alternative sources beyond pyruvate to generate acetyl-CoA for the TCA cycle. Moreover, 38E/38F cells showed disturbed gene networks mainly related to mitochondrial metabolism and the oxidation of fatty acids and glucose, which was associated with increased PGC1α, mitochondrial mass, and cellular size/complexity. Our results indicate that SETD2 deficiency induces a metabolic switch toward enhanced oxidative phosphorylation in ccRCC, which can be related to PGC1α-mediated metabolic networks. Therefore, this current study lays the foundation for the further development of a global metabolic analysis of cancer cells in individual patients, which ultimately will have significant potential for the discovery of novel therapeutics and precision medicine in SETD2-inactivated ccRCC.

KW - clear cell renal cell carcinoma (ccRCC)

KW - mitochondria

KW - oxidative phosphorylation

KW - PGC1α

KW - SETD2

UR - http://www.scopus.com/inward/record.url?scp=85059563563&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85059563563&partnerID=8YFLogxK

U2 - 10.1021/acs.jproteome.8b00628

DO - 10.1021/acs.jproteome.8b00628

M3 - Article

VL - 18

SP - 331

EP - 340

JO - Journal of Proteome Research

JF - Journal of Proteome Research

SN - 1535-3893

IS - 1

ER -